These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 33120494

  • 1. [The effect of endocapillary hypercellularity lesions on the renal prognosis and response to immunosuppressive therapy in IgA nephropathy].
    Yang HY, Shi SF, Wang SX, Lyu JC, Zhang H.
    Zhonghua Nei Ke Za Zhi; 2020 Nov 01; 59(11):894-897. PubMed ID: 33120494
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression.
    Chakera A, MacEwen C, Bellur SS, Chompuk LO, Lunn D, Roberts ISD.
    J Nephrol; 2016 Jun 01; 29(3):367-375. PubMed ID: 26318019
    [Abstract] [Full Text] [Related]

  • 3. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation.
    Shen XH, Liang SS, Chen HM, Le WB, Jiang S, Zeng CH, Zhou ML, Zhang HT, Liu ZH.
    J Nephrol; 2015 Aug 01; 28(4):441-9. PubMed ID: 25585823
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of crescent formation as a predictive marker in immunoglobulin A nephropathy: a systematic review and meta-analysis.
    Shao X, Li B, Cao L, Liang L, Yang J, Wang Y, Feng S, Wang C, Weng C, Shen X, Jiang H, Chen J.
    Oncotarget; 2017 Jul 11; 8(28):46436-46448. PubMed ID: 28526805
    [Abstract] [Full Text] [Related]

  • 5. A validation study of crescents in predicting ESRD in patients with IgA nephropathy.
    Zhang X, Shi S, Ouyang Y, Yang M, Shi M, Pan X, Lv J, Wang Z, Ren H, Shen P, Wang W, Zhang H, Xie J, Chen N.
    J Transl Med; 2018 May 03; 16(1):115. PubMed ID: 29724226
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.
    Hou JH, Le WB, Chen N, Wang WM, Liu ZS, Liu D, Chen JH, Tian J, Fu P, Hu ZX, Zeng CH, Liang SS, Zhou ML, Zhang HT, Liu ZH.
    Am J Kidney Dis; 2017 Jun 03; 69(6):788-795. PubMed ID: 28215945
    [Abstract] [Full Text] [Related]

  • 8. Crescentic IgA nephropathy in children.
    Shima Y, Nakanishi K, Hama T, Mukaiyama H, Sato M, Tanaka Y, Tanaka R, Kaito H, Nozu K, Sako M, Iijima K, Yoshikawa N.
    Pediatr Nephrol; 2020 Jun 03; 35(6):1005-1014. PubMed ID: 31993782
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide.
    Ma F, Yang X, Zhou M, Bai M, Zhao L, Li L, Dong R, Liu C, Li R, Sun S.
    J Nephrol; 2020 Dec 03; 33(6):1241-1250. PubMed ID: 32447619
    [Abstract] [Full Text] [Related]

  • 11. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.
    Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J, IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology SocietyHospital Británico de Buenos Aires, Argentina., Conference Participants.
    Kidney Int; 2017 May 03; 91(5):1014-1021. PubMed ID: 28341274
    [Abstract] [Full Text] [Related]

  • 12. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S, Li JP.
    Trials; 2020 Jan 06; 21(1):31. PubMed ID: 31907076
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical course of Immunoglobulin A nephropathy with crescents in a multi-ethnic Southeast Asian cohort.
    Lim CC, Baikunje S, Choo JCJ, Tan PH, Foo M, Woo KT.
    Nephrology (Carlton); 2020 Sep 06; 25(9):708-713. PubMed ID: 32400945
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The effect of fibrinoid necrosis on the clinical features and outcomes of primary IgA nephropathy.
    Chen H, Liu Y, Wei L, Wang H, Zheng Z, Yan T, Jia J, Li D.
    BMC Nephrol; 2023 Dec 11; 24(1):366. PubMed ID: 38082385
    [Abstract] [Full Text] [Related]

  • 17. Reproducibility of the Oxford classification of immunoglobulin A nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: evidence from the VALidation of IGA study cohort.
    Bellur SS, Roberts ISD, Troyanov S, Royal V, Coppo R, Cook HT, Cattran D, Arce Terroba Y, Asunis AM, Bajema I, Bertoni E, Bruijn JA, Cannata-Ortiz P, Casartelli D, Maria Di Palma A, Ferrario F, Fortunato M, Furci L, Gakiopoulou H, Galesic Ljubanovic D, Giannakakis K, Gomà M, Gröne HJ, Gutiérrez E, Asma Haider S, Honsova E, Ioachim E, Karkoszka H, Kipgen D, Maldyk J, Mazzucco G, Orhan D, Ozluk Y, Pantzaki A, Perkowska-Ptasinska A, Riispere Z, Soderberg MP, Steenbergen E, Stoppacciaro A, Sundelin Von Feilitzen B, Tardanico R.
    Nephrol Dial Transplant; 2019 Oct 01; 34(10):1681-1690. PubMed ID: 30561721
    [Abstract] [Full Text] [Related]

  • 18. The features in IgA-dominant infection-related glomerulonephritis distinct from IgA nephropathy: a single-center study.
    Handa T, Kakita H, Tateishi Y, Endo T, Suzuki H, Katayama T, Tsukamoto T, Muso E.
    Clin Exp Nephrol; 2018 Oct 01; 22(5):1116-1127. PubMed ID: 29564665
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.
    Coppo R, D'Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, Cattran D, Cook TH, Feehally J, Tesar V, Maixnerova D, Peruzzi L, Amore A, Lundberg S, Di Palma AM, Gesualdo L, Emma F, Rollino C, Praga M, Biancone L, Pani A, Feriozzi S, Polci R, Barratt J, Del Vecchio L, Locatelli F, Pierucci A, Caliskan Y, Perkowska-Ptasinska A, Durlik M, Moggia E, Ballarin JC, Wetzels JFM, Goumenos D, Papasotiriou M, Galesic K, Toric L, Papagianni A, Stangou M, Benozzi L, Cusinato S, Berg U, Topaloglu R, Maggio M, Ots-Rosenberg M, D'Amico M, Geddes C, Balafa O, Quaglia M, Cravero R, Lino Cirami C, Fellstrom B, Floege J, Egido J, Mallamaci F, Zoccali C, ERA-EDTA Immunonephrology Working Group.
    Nephrol Dial Transplant; 2020 Jun 01; 35(6):1002-1009. PubMed ID: 30418652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.